Application of NFAT1 gene in preparation of kit for diagnosing or treating pancreatic cancer and pulmonary fibrosis

By inhibiting NFAT1 gene expression and reducing C-MET expression, the problem of cell migration ability in pancreatic cancer and lung fibrosis is solved, providing new treatment ideas and improving treatment effects.

CN119015422APending Publication Date: 2024-11-26JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411128010.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There are challenges in the diagnosis and treatment of pancreatic cancer and pulmonary fibrosis, especially due to the strong occultity of pancreatic cancer and the limitations of traditional treatment methods, and the lack of effective targeted therapeutic targets and mechanisms.

Method used

By inhibiting NFAT1 gene expression, NFAT1 inhibitors are used to reduce C-MET gene expression, thereby weakening the migration ability of pancreatic cancer cells and lung epithelial cells, providing a new diagnostic and therapeutic idea.

Benefits of technology

It effectively reduces the migration ability of pancreatic cancer cells and lung epithelial cells, provides new targeted treatment methods, and improves the therapeutic effect of pancreatic cancer and lung fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015422A_ABST
    Figure CN119015422A_ABST
Patent Text Reader

Abstract

The invention discloses application of an NFAT1 gene in preparation of a kit for diagnosing or treating pancreatic cancer and pulmonary fibrosis, and belongs to the technical field of biological medicines. High expression of NFAT1 on pancreatic cancer cells and pulmonary epithelial cells is studied, the NFAT1 gene promotes migration of the pancreatic cancer cells and the pulmonary epithelial cells by positively regulating a C-MET gene, and a novel treatment thought is provided for treating pancreatic cancer and pulmonary fibrosis. In addition, the invention further provides a method for reducing C-MET gene expression, NFAT1 gene expression is intervened by using the NFAT1 inhibitor, then the C-MET gene expression level can be reduced, a new research idea is provided for targeted therapy, and a novel application field is provided for cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a kit for preparing NFAT1 gene for diagnosing or treating pancreatic cancer and pulmonary fibrosis, belonging to the technical field of biomedicine. Background Art

[0002] About 90% of pancreatic cancers originate from ductal adenocarcinoma of the glandular epithelium. There is a lack of effective diagnostic markers, and pancreatic cancer is highly occult. When symptoms appear, tumor cells have already metastasized locally or distally, and the 5-year survival rate is only 12%. Due to the special anatomical location of the pancreas, radiotherapy, chemotherapy or surgical treatment is more difficult. Therefore, reducing the migration and invasion of pancreatic cancer cells is particularly important for cancer patients. Targeted therapy specifically kills tumor cells and inhibits the growth, apoptosis and metastasis of cancer cells by identifying, binding to or inhibiting cancer-related biomarkers. There is an urgent need to find new targets or new regulatory mechanisms and signaling pathways for regulating pancreatic cancer metastasis.

[0003] Nuclear Factor Of Activated T Cells 2 (NFAT1) is a member of the nuclear factor of activated T cells (NFAT) family and is a protein-coding gene. This gene is expressed in a variety of tissues and organs of animals. Its main function is to act as a nuclear factor of activated T cell transcription complexes, thereby inducing the expression of downstream genes, thereby exerting corresponding functions. In addition, NFAT1 is highly expressed in gastric cancer, lung cancer, and colorectal cancer, and promotes the invasion and metastasis of cancer cells, making it a potential target for tumor treatment.

[0004] Cellular-mesenchymal epithelial transition factor (C-MET) is a member of the receptor tyrosine kinase family. The C-MET signaling pathway plays a key role in invasive growth during embryonic development and postnatal organ regeneration. Usually, the C-MET signaling pathway is fully activated in adults only during wound healing and tissue regeneration, but the tumor C-MET signaling pathway can be frequently activated by cancer cells, promoting tumor formation, invasive growth and metastasis, and is a potential target for tumor treatment.

[0005] In pancreatic ductal adenocarcinoma (PDAC), the abundant stroma is partly responsible for its malignancy. Anti-fibrotic therapy has received widespread attention in recent studies. In the late stage of pancreatic cancer, it may metastasize to the lungs through the blood circulation or lymphatic system, causing pulmonary fibrosis. Pulmonary fibrosis is a terminal manifestation of interstitial lung disease. This disease is characterized by fibroblast proliferation and a large amount of extracellular matrix deposition, leading to the destruction of lung tissue structure. The survival rate of pulmonary fibrosis is second only to lung cancer, and the survival period is very short. In recent years, studies have found that drugs used for pulmonary fibrosis can act on pancreatic cancer tumors through a certain signaling pathway.

[0006] Although studies have shown that NFAT1 and C-MET are significantly overexpressed in a variety of cancer tissues and can serve as potential targets for tumor treatment, there are currently no reports on the therapeutic effects of targeting NFAT1 and then associating C-MET to inhibit its mRNA and protein levels in pancreatic cancer and pulmonary fibrosis, thereby reducing the migration ability of pancreatic cancer cells and lung epithelial cells. Summary of the invention

[0007] In view of the above problems, the present invention found that the TCGA database showed that the high expression of NFAT1 and C-MET has clinical significance. Both NFAT1 and C-MET inhibitors significantly inhibited the migration ability of pancreatic cancer cells CFPAC-1 and PATU8988, and significantly reduced their activity. C-MET and CD44 proteins were downregulated with the inhibition of NFAT1 inhibitors, providing new ideas for tumor prognosis and targeted therapy of PAAD. In addition, NFAT1 can inhibit the migration ability of lung epithelial cells BEAS by regulating C-MET, providing new ideas for the treatment of pulmonary fibrosis.

[0008] The Gene ID of NFAT1 described in the present invention is 4773, and may also be NM_012340.5, NM_173091.4, NM_001136021.3, NM_001258294.2; including but not limited to the above accession numbers.

[0009] The Gene ID of C-MET described in the present invention is 4233, which may also be NM_001127500.3, NM_001324401.3, NM_001324402.2; including but not limited to the above accession numbers.

[0010] The present invention provides an application of an NFAT1 inhibitor in the preparation of a drug for treating pancreatic cancer with elevated cell migration level or pulmonary fibrosis. The drug is for reducing the expression level of NFAT1 gene in pancreatic cancer and lung epithelium.

[0011] In one embodiment of the present invention, the drug contains the above-mentioned NFAT1 inhibitor and pharmaceutically acceptable excipients. In one embodiment of the present invention, the inhibitor includes a nucleic acid inhibitor or a protein inhibitor.

[0012] In one embodiment of the present invention, the nucleic acid inhibitor includes siRNA, shRNA, ribozyme, and antisense oligonucleotide.

[0013] In one embodiment of the present invention, the protein inhibitor comprises an antibody that neutralizes NFAT1.

[0014] In one embodiment of the present invention, the NFAT1 inhibitor comprises the interfering RNA sequence and a vector, and the vector is a viral vector or a non-viral vector.

[0015] In one embodiment of the present invention, the viral vector includes lentivirus, pseudovirus, adenovirus, adeno-associated virus, foamy virus, herpes simplex virus, antiretroviral, cytomegalovirus vector; the non-viral vector includes an artificially synthesized or natural compound that can form a complex with plasmid DNA or gene editing fragment and promote intracellular gene transfer; the carrier material is such as lipids, polymers, proteins and polypeptides, and can use exosomes to carry the interfering RNA sequence or the recombinant gene fragment containing the interfering RNA sequence; the reagent for inhibiting the NFAT1 gene includes shRNA of the NFAT1 gene, siRNA of the NFAT1 gene, small molecule compounds that inhibit the expression of the NFAT1 gene, and monoclonal antibodies of NFAT1. The TT at the 3' end of the sense chain is two pendant bases.

[0016] The present invention also provides a method for screening drugs, wherein the drug is a C-MET inhibitor, and the method comprises:

[0017] In the test group, the test compound is added to the culture system, and the expression level and / or activity of NFAT1 in the test group is observed; in the control group, the test compound is not added to the same culture system, and the expression level and / or activity of NFAT1 in the control group is observed;

[0018] If the expression level and / or activity of NFAT1 in the test group is lower than that in the control group, it indicates that the test compound is a C-MET inhibitor.

[0019] In one embodiment of the present invention, in the test group, the expression level and / or activity of NFAT1 is detected after the test compound is co-incubated with CFPAC-1 pancreatic cancer cells.

[0020] The present invention also provides a method for constructing a cell model for screening C-MET inhibitors, the method comprising: in a test group, adding a test compound to a culture system, co-incubating the test compound with CFPAC-1 pancreatic cancer cells, and observing the expression level and / or activity of NFAT1 in the test group; in a control group, not adding the test compound to the same culture system, and observing the expression level and / or activity of NFAT1 in the control group;

[0021] If the expression level and / or activity of NFAT1 in the test group is lower than that in the control group, it indicates that the test compound is a C-MET inhibitor.

[0022] The present invention also provides a method for screening a drug that reduces the migration of lung epithelial cells, the method comprising:

[0023] In the test group, the test compound is added to the culture system, and the expression amount and / or activity of NFAT1 and / or C-MET in the test group is observed; in the control group, the test compound is not added to the same culture system, and the expression amount and / or activity of NFAT1 and / or C-MET in the control group is observed;

[0024] If the expression level and / or activity of NFAT1 and / or C-MET in the test group is lower than that in the control group, it indicates that the test compound is a drug that weakens the migration of lung epithelial cells, and the drug is used to treat pulmonary fibrosis.

[0025] The present invention also provides a method for constructing a cell model for screening and reducing the migration of lung epithelial cells, the method comprising: in a test group, adding a test compound to a culture system, co-incubating the test compound and BEAS-2B cells, and observing the expression and / or activity of NFAT1 and / or C-MET in the test group; in a control group, not adding the test compound to the same culture system, and observing the expression and / or activity of NFAT1 and / or C-MET in the control group;

[0026] If the expression level and / or activity of NFAT1 and / or C-MET in the test group is lower than that in the control group, it indicates that the test compound is a drug that weakens the migration of lung epithelial cells, and the drug is used to treat pulmonary fibrosis.

[0027] The present invention also provides an application of NFAT1 gene in preparing a kit for diagnosing or treating pancreatic cancer with elevated cell migration level and pulmonary fibrosis. The expression level of NFAT1 gene is positively correlated with cell migration-related protein C-MET.

[0028] In one embodiment of the present invention, the pancreatic cancer with elevated cell migration level is characterized by elevated C-MET expression levels in pancreatic cancer and lung epithelial tissues, and elevated migration abilities of pancreatic cancer and lung epithelial cells. The therapeutic agent for pancreatic cancer with elevated cell migration level is an agent that reduces the expression level of NFAT1 gene in pancreatic cancer and lung epithelium.

[0029] In one embodiment of the present invention, the therapeutic agent is the NFAT1 inhibitor VIVIT.

[0030] In one embodiment of the present invention, the NFAT1 inhibitor can reduce the expression of NFAT1 and thus reduce the expression of C-MET gene, while reducing the migration ability of pancreatic cancer cells and lung epithelial cells.

[0031] In one embodiment of the present invention, the concentration of the NFAT1 inhibitor in pancreatic cancer cells CFPAC-1 and PATU-8988 is 10uM and 100nM respectively, and the concentration in lung epithelial cells is 100nM, which is used to reduce the expression of NFAT1 gene.

[0032] In one embodiment of the present invention, the interfering RNA sequence is delivered by methods including needle injection, gene gun, electroporation, ultrasonic treatment and fluid dynamics.

[0033] In one embodiment of the present invention, the kit is clinically and practically applied in inhibiting cell migration in pancreatic cancer and pulmonary fibrosis.

[0034] The present invention provides a method for reducing C-MET gene expression. The method inhibits NFAT1 gene expression by using an NFAT1 inhibitor, thereby reducing the gene expression level of C-MET.

[0035] In one embodiment of the present invention, the method can be performed by adding an NFAT1 inhibitor to the cell culture, culturing, extracting RNA, performing cDNA inversion, and performing qPCR to verify at the transcription level that the expression of NFAT1 decreases while the expression of C-MET decreases;

[0036] In one embodiment of the present invention, the method can be performed by adding NFAT1 inhibitor to cell culture, culturing, collecting protein, measuring BCA concentration, and measuring WB at the protein level to verify that C-MET expression decreases after NFAT1 expression decreases;

[0037] The present invention provides a method for inhibiting the migration of pancreatic cancer and lung epithelial cells. The method can reduce the expression of NFAT1 by adding an NFAT1 inhibitor, thereby reducing the expression of C-MET, thereby causing a decrease in cell migration rate.

[0038] In one embodiment of the present invention, the method can be performed by a transwell invasion chamber assay by plating 4×10 4 cells, add 1% FBS culture medium to the upper layer of the chamber, add 10% FBS culture medium to the lower layer of the chamber, fix and stain the cells after 72 hours of cell culture, take pictures under a microscope and count the number of cells to verify that the migration ability of the cells decreases after the addition of the inhibitor;

[0039] In one embodiment of the present invention, the pancreatic cancer cell culture medium is RPMI culture medium, and the lung epithelial cell culture medium is DMEM culture medium.

[0040] The present invention also provides a qRT-PCR primer for detecting NFAT1 and C-MET, comprising an upstream primer and a downstream primer, the sequence of which is:

[0041] NFAT1 upstream primer, GATAGTGGGCAACACCAAAGTCC;

[0042] NFAT1 downstream primer, TCTCGCCTTTCCGCAGCTCAAT;

[0043] C-MET upstream primer, CCACGGGACAACACAATACA;

[0044] C-MET downstream primer, TAAAGTGCCACCAGCCATAG.

[0045] The present invention provides a method for screening a drug, wherein the drug is an NFAT1 inhibitor, and the method comprises:

[0046] In the test group, a test compound is added to the culture system, and the expression amount and / or activity of C-MET in the test group is observed; in the control group, no test compound is added to the same culture system, and the expression amount and / or activity of C-MET in the control group is observed;

[0047] If the expression level and / or activity of C-MET in the test group is lower than that in the control group, it indicates that the test compound is a NFAT1 inhibitor.

[0048] In one embodiment of the present invention, in the test group, the expression level and / or activity of C-MET is detected after the test compound is co-incubated with CFPAC-1 pancreatic cancer cells.

[0049] The present invention also provides a method for constructing a cell model for screening NFAT1 inhibitors, the method comprising: in a test group, adding a test compound to a culture system, co-incubating the test compound with CFPAC-1 pancreatic cancer cells, and observing the expression amount and / or activity of C-MET in the test group; in a control group, not adding the test compound to the same culture system, and observing the expression amount and / or activity of C-MET in the control group;

[0050] If the expression level and / or activity of C-MET in the test group is lower than that in the control group, it indicates that the test compound is a NFAT1 inhibitor.

[0051] Beneficial Effects

[0052] Compared with the prior art, the present invention has the following advantages:

[0053] (1) Compared with traditional methods such as surgical treatment and chemotherapy, this invention reveals and verifies a new diagnostic and therapeutic target for pancreatic cancer, starting from the molecular mechanism of proliferation, invasion and migration, and providing a new idea for the treatment of pancreatic cancer;

[0054] (2) The present invention reveals the changes in gene expression levels in pancreatic cancer, providing a new method for the difficulty in early detection and diagnosis of pancreatic cancer;

[0055] (3) The present invention reduces NFAT1 gene expression by adding NFAT1 inhibitor, thereby reducing C-MET gene expression, and ultimately reducing the migration ability of pancreatic cancer cells and lung epithelial cells;

[0056] (4) The present invention breaks through the traditional treatment ideas and starts from the level of molecular expression, scratches and migration mechanism of lung epithelial cells, providing new ideas and methods for the diagnosis and treatment of pulmonary fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 : Expression of NFAT1 in tumor tissues and normal tissues; wherein, a is the expression difference diagram of NFAT1 in different tumor tissues and normal tissues; b is the differential expression diagram of NFAT1 in pancreatic cancer (PAAD) and normal tissues; c is the expression level of NFAT1 in different stages of pancreatic cancer; d is the survival rate difference comparison diagram of different expression levels of NFAT1.

[0058] Figure 2 : Expression of C-MET in tumor tissue and normal tissue; 2a is the expression difference diagram of C-MET in tumor tissue and normal tissue; 2b is the differential expression diagram of C-MET in pancreatic cancer and normal tissue; 2c is the expression level of C-MET in different stages of pancreatic cancer; 2d is the survival rate difference comparison diagram of different expression levels of C-MET.

[0059] Figure 3 : There is a correlation between NFAT1 and C-MET; among them, 3a is that NFAT1 and C-MET are correlated in expression in pancreatic cancer and interact with multiple cytokines; 3b is that NFAT1 and C-MET are positively correlated in pancreatic cancer tissue.

[0060] Figure 4 : In pancreatic cancer tissue, NFAT1 positively regulates C-MET and promotes the migration of pancreatic cancer cells; among them, 4a verifies at the transcriptional level that NFAT1 positively regulates the expression of C-MET gene in pancreatic cancer cells after knocking down the NFAT1 gene; 4b verifies at the transcriptional level that NFAT1 positively regulates the expression of C-MET gene in pancreatic cancer cells after adding NFAT1 inhibitor; 4c verifies at the protein level the difference in expression levels and correlation between NFAT1 and C-MET after using NFAT1 inhibitor; 4d is a cell scratch experiment to detect the migration ability of pancreatic cancer cells after adding NFAT1 inhibitor; 4e is a Transwell experiment to detect the migration ability of pancreatic cancer cells after adding NFAT1 inhibitor; 4f is a Transwell experiment to verify the migration ability of pancreatic cancer cells after overexpressing NFAT1.

[0061] Figure 5 : In lung epithelial tissue, NFAT1 positively regulates C-MET, and the addition of NFAT1 inhibitors significantly weakened the migration of lung epithelial cells; 5a is a protein level verification of the difference and correlation between the expression levels of NFAT1 and C-MET on BEAS cells after the addition of NFAT1 inhibitors; 5b is a cell scratch experiment to verify the migration ability of BEAS lung epithelial cells after the use of NFAT1 inhibitors; 5c is a transwell migration chamber experiment to verify the migration ability of BEAS lung epithelial cells after the use of NFAT1 inhibitors.

[0062] Figure 6 : Specific implementation diagram of adding NFAT1 inhibitor to CFPAC-1 pancreatic cancer cells.

[0063] Figure 7 : Specific implementation diagram of adding NFAT1 inhibitor to PATU-8988 pancreatic cancer cells.

[0064] Figure 8 : Specific implementation diagram of BEAS lung epithelial cells plus NFAT1 inhibitor.

[0065] Fig. 9 : Difference and correlation of NFAT1 and C-MET expression levels at the transcriptional level in ASPC-1 pancreatic cancer cells with sh C-MET. DETAILED DESCRIPTION

[0066] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0067] In the present invention, NFAT1 is a member of the nuclear factor of activated T cells (NFAT) family and is a protein coding gene. This gene is expressed in various tissues and organs of animals, and its main function is to activate the nuclear factor of T cell transcription complex, and then induce the expression of downstream genes, so as to play a corresponding function. NFAT1 is expressed in various tissues and organs of mammals, and also plays an important role in malignant tumors. NFAT1 is highly expressed in gastric cancer, lung cancer, and colorectal cancer, and promotes the invasion and metastasis of cancer cells, and is a potential tumor treatment target.

[0068] In the present invention, C-MET is a member of the receptor tyrosine kinase family, and the C-MET signaling pathway plays a key role in invasive growth during embryonic development and postpartum organ regeneration. Usually, the C-MET signaling pathway is fully activated only during wound healing and tissue regeneration in adults, but the tumor C-MET signaling pathway can be frequently activated by cancer cells, promoting tumor formation, invasive growth and metastasis, and is a potential target for tumor treatment.

[0069] The "embodiment" or "implementation" or "in another embodiment" or "in certain embodiments" or "in some embodiments of the present application" mentioned throughout the specification means that the specific reference elements, structures or features related to the embodiment are included in at least one embodiment. Therefore, the phrases "in one embodiment" or "in an embodiment" or "in another embodiment" or "in certain embodiments" or "in some embodiments of the present application" appearing in different places throughout the specification do not necessarily all refer to the same embodiment. In addition, specific elements or features can be combined in one or more embodiments in any appropriate manner.

[0070] Unless otherwise required in this application, throughout the specification and the claims that follow, the word "comprise" and its English variations such as "comprises" and "comprising" should be interpreted in an open, inclusive sense, i.e., "including but not limited to".

[0071] It should be understood that the singular articles "a," "an," and "the," as used in this specification and the appended claims, include plural referents unless the context clearly dictates otherwise.

[0072] Target Usage

[0073] The present invention uses NFAT1 and C-MET as targets to prepare drugs for treating pancreatic cancer pulmonary fibrosis by regulating C-MET with NFAT1, including but not limited to NFAT1 inhibitors.

[0074] Gene use

[0075] The NFAT1 gene in the present invention can be used as a target gene for gene therapy, and related biological reagents can be designed and prepared to achieve the purpose of prevention or treatment through genetic engineering technology.

[0076] Drug Use

[0077] The present invention provides use of drugs targeting NFAT1 and C-MET in treating pancreatic cancer and pulmonary fibrosis.

[0078] The corresponding drugs can inhibit the expression of NFAT1 and C-MET, thereby reducing the migration ability of pancreatic cancer cells and lung epithelial cells. The following examples are used to illustrate but not to limit the determination method of the present invention.

[0079] The culture medium involved in the following examples is as follows:

[0080] RPMI complete medium: 90% RPMI-1640 cell basal medium + 10% fetal bovine serum (FBS).

[0081] DMEM complete medium: 90% DMEM basal medium + 10% fetal bovine serum (FBS).

[0082] The experimental materials and reagents involved in the following examples are as follows:

[0083] Experimental material information:

[0084] CFPAC-1, ASPC-1, and PATU-8988 pancreatic cancer cell lines were purchased from Procell (China), and RPMI-1640 cell basal culture medium was purchased from Dalian Meilun Biotechnology Co., Ltd.; qPCR primers (Sangon, China), Anti-βActin Mouse Monoclonal Antibody (Yifeixue, China), Stripping Buffer (Kangwei Century, China), BeyoColorTM color pre-stained protein molecular weight standard (10-170kD) (Biyuntian, China), SDS-PAGE Loading Buffer (Reducing, 5×) (Kangwei Century, China), TB Premix Ex Taq TMII (Tli RNaseHPlus) (Takara, Japan), HiFiScript cDNA Synthesis Kit (Kangwei Century, China), BEAS cell line purchased from Procell (procell, China), DMEM cell basal medium (Dalian Meilun Biotechnology Co., Ltd.), T12.5 cell culture flask (Ke Chuang, China), cell scraper (NEST, China), 1.5 mL EP tube (Hengkang, China), BCA protein concentration determination kit (Biyuntian, P0010), 96-well plate (NEST, China), SDS-PAGE gel preparation kit (Biyuntian, China), BeyoColorTM color pre-stained protein molecular weight standard (Biyuntian, China), Stripping Buffer (Kangwei Century, China), polyvinylidene fluoride (PVDF) membrane, cell counting plate, counter.

[0085] Reagent Information:

[0086] Penicillin-streptomycin solution and 0.25% trypsin (containing EDTA and phenol red) (Biosharp LifeSciences, China), mycoplasma remover (Novozyme, China), phosphate buffered saline (PBS) (Boster, China), dimethyl sulfoxide (DMSO) (Sigma, USA), serum (NSERA, South America), NFAT1 inhibitor VIVIT (MCE, China); BeyoECL Star (ECL chemiluminescence kit) (Biyuntian, China), Signal UpTM Western detection sensitizer (Biyuntian, China), skim milk powder (Biyuntian, China), NaCl (Sinopharm, China), glycine (Sinopharm, China), Tris-base (Meilun, China), methanol (Sinopharm, China), SDS sodium dodecyl sulfate (Biofroxx, Germany), SDS-PAGE gel preparation kit (Biyuntian, China), BCA kit (Novozyme, China), DEPC water (Biyuntian, China), ethanol (Sinopharm, China), isopropanol (Sinopharm, China), chloroform (Sinopharm, China), Trizol (Ambion life sciencestechnology, USA), crystal violet (Sinopharm, China).

[0087] Fetal bovine serum (FBS) (NSERA, South America), sodium dodecyl sulfate (Biofrox, Germany), Tris base (Tris(hydroxymethyl)aminomethane) (Dalian Meilun, China), glycerol (Sinopharm Group, China), glycine (Sinopharm Group, China), sodium chloride (Sinopharm Group, China), Tween 20 (Inokai, China), SDS-PAGE Loading Buffer (Reducing, 5×) (Kangwei Century, China), anhydrous methanol (Sinopharm Group, China), NFAT1 inhibitor VIVIT (MCE, China), crystal violet (Sinopharm, China), skim milk powder (Biyuntian, P0216), BeyoECL Plus (Biyuntian, P0018S), Signal UPTM Western detection sensitizer (Biyuntian, P0272), Anti-β-actin mAb (Mouse) (Yifexue Biotechnology, YFMA0052), CD44 Mouse mAb (CST, 5640S), Goat-Anti-Rabbit IgG (CWBIO, CW0103), Goat-Anti-Mouse IgG (CWBIO, CW0102), C-MET Mouse mAb (CST, 3127S), NRF2 Rabbit mAb (CST, 12721T).

[0088] The primers and sequences involved in the following examples are as follows:

[0089] Table 1: Primer sequences

[0090] β-actin upstream primer TCCTCCTGAGCGCAAGTA β-actin downstream primers CTGCTTGCTGATCCACATCT NFAT1 upstream primer GATAGTGGGCAACACCAAAGTCC NFAT1 downstream primers TCTCGCCTTTCCGCAGCTCAAT C-MET upstream primer CCACGGGACAACACAATACA C-MET downstream primers TAAAGTGCCACCAGCCATAG

[0091] The culture medium involved in the following examples is as follows:

[0092] RPMI-1640 medium: D-glucose, phenol red, L-glutamine.

[0093] DMEM medium: D-glucose (4500 mg / L), phenol red, L-glutamine, sodium pyruvate.

[0094] The experimental reagents involved in the following examples are as follows:

[0095] Table 2: 1x Laemmli buffer (pH = 6.8) composition

[0096] Reagents Dosage SDS Sodium Dodecylbenzene Sulfonate 2g Tris base 1.528g glycerin 20mL dd water Add to 200mL

[0097] Table 3: 8% separation gel composition (15mL system)

[0098] Reagents Volume (mL) dd water 7.1 30% Acr-Bis (29:1) 4.0 Gel buffer A 3.75 10% APS 0.15 TEMED 0.009

[0099] Table 4: Concentrated gel composition (6 mL system)

[0100] Reagents Volume (mL) dd water 2.0 30% Acr-Bis (29:1) 1.0 Gel buffer B 3.0 10% APS 0.06 TEMED 0.006

[0101] Table 5: Running solution formula (pH = 8.3)

[0102] Reagents 1x 10x Tris 3g 30g Glycine 14.4g 144g SDS Sodium Dodecylbenzene Sulfonate 1 g 10g Volume (dd water) 1L 1L

[0103] Table 6: Transfer solution formula (pH = 8.3)

[0104] Reagents 1x 10x Tris 3g 30g Glycine 14.4g 144g C-METhanol 200ml —— volume 1L 1L (10x) + 2L methanol + 7L dd water = 10L (1x)

[0105] Table 7: TBST eluent formula (pH = 7.4)

[0106] Reagents 1x 10x 1M Tris, pH 7.4 1ml 12.1g 5M NaCl 3ml 87.66g Tween 20 1ml 10ml volume 1L 1L

[0107] The detection methods involved in the following embodiments are as follows:

[0108] Extraction of total cellular RNA

[0109] Remove the culture medium of the cells, add 500μL Trizol solution to protect RNA to cover all cells, let it stand for 5-10 minutes, use a cell scraper to collect the contents of the culture dish or culture bottle, and transfer the liquid to the EP tube. If RNA is not extracted immediately, the sample can be stored in a -80℃ refrigerator for later use. When extracting RNA, add chloroform solution at a ratio of Trizol:chloroform = 5:1, shake the EP tube vigorously, place it at room temperature for 8-10 minutes, and centrifuge it at 12000rpm at 4℃ for 15 minutes. Use a pipette to transfer the upper transparent aqueous phase containing RNA to a new EP tube without RNAse, and do not absorb the DNA layer or other substances in the phenol-containing protein layer. Add an equal amount of isopropanol solution according to the volume of the absorbed aqueous phase, shake it several times, place it in a 4℃ refrigerator for 2-3 hours, and then centrifuge it at 12000rpm at 4℃ for 10 minutes, and carefully pour out the supernatant. Add 500 μL of 75% frozen ethanol solution prepared with DEPC water to the EP tube, centrifuge at 12000rpm, 4℃ for 5min, carefully pour off the upper solution, and dry it upside down at room temperature for a while (do not pour out the precipitate). Add 10-20 μL of DEPC water to the bottom of the EP tube, aspirate and mix, and measure its concentration and purity using an ultra-micrometer. A260 / 280 is close to 2.0, proving that the RNA purity is high. The measured RNA sample is stored in a -80℃ refrigerator or directly reverse transcribed into cDNA and stored in a -20℃ refrigerator.

[0110] cDNA reverse transcription

[0111] Prepare the reagents according to the reverse transcription cDNA reaction system of Kangwei Century Company, vortex and shake to mix, centrifuge briefly, place in a dry thermostat, and set the program as follows: 25℃5min; 42℃30min; 85℃5min. After the reaction, store in a -20℃ refrigerator for later use.

[0112] Analysis of fluorescent quantitative PCR

[0113] The original cell culture medium was discarded, and the cells were rinsed twice with 1xPBS, and then Trizol was added for lysis and collection. 200 μL of chloroform was added to each sample and shaken thoroughly, and then centrifuged after standing. The supernatant was aspirated and added to isopropanol, centrifuged, and the supernatant was discarded. Then ethanol was added to each sample for washing, centrifugation, supernatant was discarded, and DEPC water was added to dissolve after opening the lid to dry. The concentration of RNA samples was measured in ng / μL on Nano one. Then 20 μL of cDNA was reverse transcribed from 1500 ng of total RNA using the HiFiscript cDNA synthesis kit. According to the instructions, TB green Premix Ex Taq II was added and real-time quantitative qRT-PCR was performed using the ThermalCycler Bio-rad qPCR Cycler. After normalization of the β-actin gene expression level, quantitative analysis was performed. The primer sequences used in this study were designed by ourselves or derived from published articles. The denaturation reaction process started at 55°C for 5 min, then 95°C for 5 min, and then 40 cycles of 95°C for 30 s and 55°C for 30 s. The melting curve program was 95°C for 15 s and 55°C for 1 min. -ΔΔCT Methods The relative expression of NFAT1 and C-MET in different cell models was analyzed to determine whether they were differentially expressed, and the data were presented in a bar graph using Prism 8.0 version (USA).

[0114] BCA method for protein concentration determination

[0115] After 24 hours of drug addition, observe the cells under a microscope and add the corresponding amount of protein lysis solution Laemmilibuffer to extract the protein sample. In the BCA protein concentration determination kit, the BCA working solution is mixed according to A solution: B solution = 49:1. Add 199μL of working solution and 1μL of protein sample to be tested to each well of the sample well, and mix by suction. First add 100μL of BCA working solution to each well of the standard sample well, then add 90μL of BCA working solution and 10μL of 2mg / mL bovine serum albumin (BSA) to the first well, mix by blowing and suction, and then draw 100μL to the second well and mix, and so on. After the last well is mixed, draw 100μL of solution and discard it, and finally add 100μL of BCA working solution to all standard curve wells. Place in a 37℃ constant temperature oscillator away from light for 30min, measure the OD value at a wavelength of 562nm with an enzyme reader, and calculate the protein concentration of each sample to be tested after drawing a standard curve. According to the volume of protein sample, add 5x SDS reducing buffer to the sample with measured protein concentration, heat it in a dry thermostat at 100°C for 10 minutes to completely denature the protein, leave it at room temperature for several minutes, and store it in a -80°C refrigerator.

[0116] Western Blot (WB)

[0117] According to the method of determining protein concentration by BCA method, protein concentration was measured using BCA kit. 6-10 μg of total protein extract was added to 8% SDS-PAGE gel at a constant voltage (80-120v) for 120 minutes, and the separation gel was transferred to PVDF membrane at 80v in a 4℃ refrigerator for 90 minutes. The PVDF membrane was blocked with 5% skim milk dissolved in TBST for 1 hour, and the primary antibodies of mouse β-actin monoclonal antibody (1:1500), rabbit NFAT1 monoclonal antibody (1:1500), mouse C-MET monoclonal antibody (1:500) and mouse CD44 monoclonal antibody (1:1500) were incubated overnight in a 4℃ refrigerator with rotation, then washed 3 times with TBST, 5 minutes each time, incubated with horseradish peroxidase HRP-conjugated secondary antibody at room temperature for 1 hour, and washed 4 times with TBST, 5 minutes each time. The immunoblot results were observed with enhanced chemiluminescence reagent (ECL) by Tianneng chemiluminescence imaging instrument.

[0118] Cell scratch assay

[0119] Take the cells grown to 90%-100% in a 6cm culture dish and evenly draw a well with a sterile 10μL pipette tip. Discard the original RPMI culture medium, wash the excess floating cells at the scratch with PBS, and then add serum-free culture medium. The experimental group added NFAT1 inhibitor according to the pre-calculated drug concentration, and the control group added the same dose of DMSO for culture. Take pictures and collect data at 0h, 16h, 24h, 32h, and 48h.

[0120] Transwell experiment

[0121] The cells in good growth state were digested with 0.25% trypsin, neutralized and diluted with complete RPMI medium, and then resuspended and counted by pipetting. The cells were plated on a sterile 12-well plate, 700 μl of complete RPMI medium was added to each well of the lower chamber, and 4×10 4 cells and 500 μl of culture medium containing 1% serum, and check to confirm that there are no bubbles between the bottom membrane of the upper chamber and the culture medium in the lower chamber. The experimental group added NFAT1 inhibitor according to the pre-calculated drug concentration, and the control group added the same dose of DMSO. After culturing in a 37°C, 5% CO2 incubator for 72 hours, the Transwell chamber was removed, the original culture medium was discarded, and 1xPBS was rinsed twice, and then fixed with 75% ethanol for 20 minutes. After fixation, 500 μl of 0.1% crystal violet was added for 20 minutes, and the upper chamber was wiped dry with a cotton swab after washing with clean water, placed under a 4x microscope, and cell migration images were collected, counted and statistically analyzed.

[0122] The method for adding the 100nM NFAT1 inhibitor group to the pancreatic cancer cells involved in the following embodiments is as follows: the original drug concentration of the NFAT1 inhibitor is 1mM, the original drug is first diluted to 100μM with DMSO at 1:10, the cell culture medium of the 12-well plate is 1000μL, and finally 1μL is added to the 12-well plate; the method for adding the 500nM NFAT1 inhibitor group to the pancreatic cancer cells is as follows: the original drug concentration of the NFAT1 inhibitor is 1mM, the original drug is first diluted to 50μM with DMSO at 1:20, the cell culture medium of the 12-well plate is 1000μL, and finally 10μL is added to the 12-well plate; the method for adding the 1μM NFAT1 inhibitor group to the pancreatic cancer cells is as follows: the original drug concentration of the NFAT1 inhibitor is 1mM, the cell culture medium of the 12-well plate is 1000μL, so 1μL is added to the 12-well plate; the concentration in the pancreatic cancer cells is 5μM The addition method of the NFAT1 inhibitor group is as follows: the original drug concentration of the NFAT1 inhibitor is 1mM, the cell culture medium of the 12-well plate is 1000μL, and 5μL is added to the 12-well plate; the concentration in pancreatic cancer cells is 10μM. The addition method of the NFAT1 inhibitor group is as follows: the original drug concentration of the NFAT1 inhibitor is 1mM, and 10μL is added to the 12-well plate.

[0123] The method for adding the 50 nM NFAT1 inhibitor group to the lung epithelial cells involved in the following embodiments is as follows: the original drug concentration of the NFAT1 inhibitor is 1 mM, the original drug is first diluted to 50 μM with DMSO at 1:20, the 12-well plate cell culture medium is 1000 μL, and finally 1 μL is added to the 12-well plate; the method for adding the 100 nM NFAT1 inhibitor group to the lung epithelial cells is as follows: the original drug concentration of the NFAT1 inhibitor is 1 mM, the original drug is first diluted to 100 μM with DMSO at 1:10, the 12-well plate cell culture medium is 1000 μL, and finally 1 μL is added to the 12-well plate; the concentration in the lung epithelial cells is 500 nM The addition method of the NFAT1 inhibitor group is as follows: the original drug concentration of the NFAT1 inhibitor is 1mM, the original drug is first diluted to 50μM with DMSO at 1:20, the cell culture medium of the 12-well plate is 1000μL, and finally 10μL is added to the 12-well plate; the concentration in pancreatic cancer cells is 1μM. The addition method of the NFAT1 inhibitor group is as follows: the original drug concentration of the NFAT1 inhibitor is 1mM, the cell culture medium of the 12-well plate is 1000μL, so 1μL is added to the 12-well plate.

[0124] Example 1: Screening of NFAT1 and C-MET genes and verification of their correlation

[0125] The specific steps are as follows:

[0126] 1. NFAT1 and C-MET gene screening

[0127] (1) Open the GEPIA database website http: / / gepia.cancer-pku.cn / , select Single Gene Analysis, enter the gene name NFAT1, click GoPIA!, and in the General column, you can analyze the expression difference between different cancer tissues and normal tissues of this gene. Select the Expression DIY column, click Boxplot, select PAAD as the cancer name, enter PAAD in Datasets, and click Plot to obtain the expression difference of NFAT1 between pancreatic cancer tissue and normal pancreatic tissue. Similarly, in the Expression DIY column, click Stage plot and perform the same operation to obtain the expression difference of NFAT1 in different stages of pancreatic cancer.

[0128] (2) Open the UALCAN data analysis website https: / / ualcan.path.uab.edu / cgi-bin / ualcan-res.pl, select the TCGA database, enter the gene name C-MET in the scan by genes box, select Pancreaticadenocarcinoma, and click Explore. Click Pan-cancer view in the Link for analysis column to obtain the expression differences of C-MET between different cancer tissues and corresponding normal tissues. Click Expression in the Link for analysis column and select sample types to obtain the expression differences of C-MET in normal pancreatic tissue and pancreatic cancer tissue. Select individual cancer stages in the drop-down bar to obtain the expression differences of C-MET in different stages of pancreatic cancer.

[0129] (3) Open the Kaplan-Meier Plotter database website https: / / kmplot.com / analysis / , select Pancreatic Cancer, enter the gene name NFAT1, click Overall survival, select Auto select best cutoff, select N1, M0, and click Draw Kaplan-Meier Plot to obtain the NFAT1 overall survival. Open the Kaplan-Meier Plotter database website https: / / kmplot.com / analysis / , select Pancreatic Cancer, enter the gene name C-MET, click Overall survival, select Auto select best cutoff, and click Draw Kaplan-Meier Plot to obtain the C-MET overall survival. Open the GEPIA database website http: / / gepia.cancer-pku.cn / , select Survival Analysis, enter the gene name C-MET, click Disease Free Survival (RFS), enter PAAD in Datasets, and click Plot to obtain the C-MET disease-free survival.

[0130] 2. There is a correlation between NFAT1 and C-MET

[0131] (1) Open the STRING database website https: / / cn.string-db.org / , click search, enter NFAT1 and MET in the "protein name" field, select Homo sapiens as the organism, click search, select the correct gene, click continue, and analyze the correlation between NFAT1 and MET.

[0132] (2) Open the TIMER database http: / / timer.cistrome.org / , click Cancer Exploration, select Gene_Corr, enter NFAT1 and MET in Interested Gene and Gene Expression, respectively, click Submit, enter PAAD in Search, and analyze the positive correlation between NFAT1 and MET in pancreatic cancer tissues.

[0133] 3. Results

[0134] The results show:

[0135] Figure 1 and 2 a and 2a in the figure show that by comparing different pancreatic cancer tissues, NFAT1 and C-MET genes are highly expressed in pancreatic cancer tissues;

[0136] Figure 1 and 2 The results in b and 2b showed that the expression of NFAT1 and C-MET genes in pancreatic cancer tissues was higher than that in normal tissues;

[0137] from Figure 1 and 2 From c and 2c, we can see that the expression levels of NFAT1 and C-MET are different in different stages of pancreatic cancer. In different stages of pancreatic cancer, the expression levels of NFAT1 and C-MET show an overall upward trend;

[0138] exist Figure 1 and 2 d and 2d show that the survival rate of pancreatic cancer patients with high expression of NFAT1 and C-MET is significantly lower than that of patients with low expression of NFAT1 and C-MET.

[0139] exist Figure 3 The results in 3a showed that NFAT1 was correlated with C-MET and interacted with multiple cytokines. Further verification of the results in 3b showed that there was a positive correlation between NFAT1 and C-MET.

[0140] Example 2: In pancreatic cancer tissue, NFAT1 positively regulates C-MET and promotes the migration of pancreatic cancer cells

[0141] Specific implementation methods

[0142] 1. CFPAC-1 pancreatic cancer cell culture

[0143] (1) Cell recovery

[0144] Irradiate the cell room with ultraviolet light for 15 minutes, heat the water bath to 37°C in advance, thaw CFPAC-1 pancreatic cancer cells in the water bath, put the thawed cells into a centrifuge, and centrifuge at 1000 rpm for 5 minutes. After the centrifugation, take out the cryopreservation tube and discard the cryopreservation solution, add 1 ml of RPMI complete culture medium to resuspend the cells, and obtain the resuspended CFPAC-1 pancreatic cancer cells;

[0145] After adding 500ul of RPMI complete culture medium to a T12.5 cell culture flask to moisten the flask, the resuspended CFPAC-1 pancreatic cancer cells were transferred to the T12.5 flask, and the flask was shaken to evenly disperse the CFPAC-1 pancreatic cancer cells. The flask was then placed in a constant temperature incubator at 37°C and 5% CO2 for culture.

[0146] (2) Cell passaging

[0147] Observe the cells in the culture flask under a microscope. If the cell density reaches 90% and the cells are in good condition, they can be subcultured. The specific method is:

[0148] Discard the culture medium in the original culture flask, rinse the cells with 750ul of 1x PBS, and discard the buffer; add 750ul of trypsin to the culture flask, tighten the bottle cap and tap the bottle for about 3 minutes. After the cells are fully digested, add 1000ul of RPMI complete culture medium to the bottle to terminate the digestion and obtain a cell suspension;

[0149] The cell suspension was transferred to a 10 ml centrifuge tube, centrifuged at 1000 rpm for 5 min, the supernatant was discarded, and the cells were resuspended in RPMI complete medium to obtain a cell suspension;

[0150] The cell suspension was transferred to three six-well plates containing RPMI complete medium at a volume ratio of 1:3 for subculture under the following conditions: cultured in a constant temperature incubator at 37° C. and 5% CO 2 .

[0151] The cultured CFPAC-1 pancreatic cancer cells were obtained.

[0152] 2. Establishment of CFPAC-1 cell model with NFAT1 inhibition and CFPAC-1 cell model with NFAT1 overexpression

[0153] (1) Establishment of CFPAC-1 cell model for NFAT1 inhibition

[0154] NFAT1 inhibitors were prepared in DMSO and the stock concentration of the stock solution was 1 mM.

[0155] 1) When the density of the cultured CFPAC-1 pancreatic cancer cells obtained in step 1 reaches about 90%, the cells are passaged twice into a sterile 12-well plate, the cells are evenly dispersed, and cultured in a constant temperature incubator at 37° C. and 5% CO2 for about 24 hours (the cell density reaches about 60% and is evenly distributed);

[0156] 2) Add drugs to the above-mentioned sterile 12-well plate cells, and set up: a DMSO control group, and experimental groups with final concentrations of 100 nM NFAT1 inhibitor, 500 nM NFAT1 inhibitor, 1 μM NFAT1 inhibitor, 5 μM NFAT1 inhibitor, and 10 μM NFAT1 inhibitor; the original drugs diluted to the corresponding concentrations were directly added to the cultured cells, and the cells were cultured in a 37° C., 5% CO2 incubator for 24 h.

[0157] The specific groups and treatment methods are as follows:

[0158] DMSO control group: DMSO was added to the cultured cells as a control, and the final DMSO concentrations were: 100nM, 500nM, 1μM, 5μM, 10μM; the control groups were obtained: DMSO-100nM group, DMSO-500nM group, DMSO-1μM group, DMSO-5μM group, DMSO-10μM group; the control groups were placed in a 37°C, 5% CO2 incubator and cultured for 24 hours.

[0159] 100 nM NFAT1 inhibitor group: Add 100 nM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0160] 500 nM NFAT1 inhibitor group: Add 500 nM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0161] 1 μM NFAT1 inhibitor group: Add 1 μM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0162] 5 μM NFAT1 inhibitor group: Add NFAT1 inhibitor with a final concentration of 5 μM to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0163] 10 μM NFAT1 inhibitor group: Add 10 μM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0164] Specific as Figure 6 shown.

[0165] (2) Establishment of PATU-8988 cell model for NFAT1 inhibition

[0166] NFAT1 inhibitors were prepared in DMSO and the stock concentration of the stock solution was 1 mM.

[0167] 1) When the density of the cultured PATU-8988 pancreatic cancer cells obtained in step 1 reaches about 90%, the cells are subcultured twice into a sterile 12-well plate, the cells are evenly dispersed, and cultured in a constant temperature incubator at 37° C. and 5% CO2 for about 24 hours (the cell density reaches about 60% and is evenly distributed);

[0168] 2) Add drugs to the above-mentioned sterile 12-well plate cells, and set up: DMSO control group, experimental groups with final concentrations of 50nM NFAT1 inhibitor, 100nM NFAT1 inhibitor, 500nM NFAT1 inhibitor, and 1μM NFAT1 inhibitor; add the original drug diluted to the corresponding concentration directly to the cultured cells, and culture them in a 37°C, 5% CO2 incubator for 24h.

[0169] The specific groups and treatment methods are as follows:

[0170] DMSO control group: DMSO was added to the cultured cells as a control, and the final DMSO concentrations were 50nM, 100nM, 500nM, and 1μM, respectively; the control groups were obtained: DMSO-50nM group, DMSO-100nM group, DMSO-500nM group, and DMSO-1μM group; the control groups were placed in a 37°C, 5% CO2 incubator and cultured for 24h.

[0171] 50 nM NFAT1 inhibitor group: Add 50 nM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0172] 100 nM NFAT1 inhibitor group: Add 100 nM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0173] 500 nM NFAT1 inhibitor group: Add 500 nM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0174] 1 μM NFAT1 inhibitor group: Add 1 μM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0175] Specific as Figure 7 shown.

[0176] (3) Establishment of pancreatic cancer cell models with overexpression and knockdown of NFAT1

[0177] 1) 293T cells (purchased from: Prosai) and CFPAC-1 pancreatic cancer cells were laid in advance. When the cell density reached 60-70%, transfection could be started.

[0178] 2) Aspirate and discard the original DMEM basal medium in the 293T cells, replace it with serum-free and anti-antibody-free DMEM basal medium (purchased from Dalian Meilun Company), and use DMEM basal medium to dilute Lipofectamine TM 3000 reagent, let stand at room temperature for 5 min.

[0179] 3) Add lentiviral plasmid (second-generation lentiviral plasmid - pMD2.G, psPAX2) and core plasmid (shNFAT1 or NFAT1 O / E) at a ratio of pMD2.G:psPAX2:core plasmid = 2:2:1, mix gently, let stand at room temperature for 15 minutes, and then add the diluted Lipofectamine TM 3000 reagents were added to the above mixed plasmids to obtain a mixed solution.

[0180] The mixed solution was dripped into the 293T cell culture medium obtained in step 2), and placed in a 37°C, 5% CO2 incubator for transfection for 6-10 hours, and then serum-free and dual-antibody-free DMEM basal culture medium containing 10% FBS was added, and cultured for 24 hours to obtain a virus suspension;

[0181] Remove the old culture medium in the CFPAC-1 pancreatic cancer cells in step 1) and add a small amount of RPMI complete culture medium containing 10% FBS. Use a 1 mL syringe to absorb the virus suspension in the above 293T cells, filter it through a 0.45 μm filter membrane, and then add it to the corresponding CFPAC-1 pancreatic cancer cells.

[0182] Then, an appropriate amount of 1 μg / mL polybrene was added to the CFPAC-1 pancreatic cancer cell culture medium.

[0183] 4) Then, according to the above method, CFPAC-1 pancreatic cancer cells were infected for the second time and the third time at 48 hours and 72 hours after transfection, respectively.

[0184] After three infections, the culture medium of CFPAC-1 pancreatic cancer cells was replaced with full RPMI culture medium containing 10% FBS and 1% double antibody (a mixture of 100U / ml penicillin and 100μg / ml streptomycin). When the cells grow well, add filtered sterile 1ug / mL puromycin to the culture medium and screen for 14 days. During this period, pay attention to observe the cell state and replace the full culture medium containing puromycin every 2-3 days.

[0185] Finally, we obtained a pancreatic cancer cell model with knockdown of NFAT1 and a pancreatic cancer cell model with overexpression of NFAT1. After the experiment, we detected the relative expression of NFAT1 and C-MET in different cell models, the expression of NFAT1 and C-MET proteins after using NFAT1 inhibitor, cell scratch assay and transwell assay. The results are as follows:

[0186] Experimental results:

[0187] 1) After the experiment, total RNA was extracted from cells using 2 -ΔΔCT Methods The relative expression of NFAT1 and C-MET in different cell models was analyzed to see if there was differential expression, and the data were presented as a bar graph using Prism version 8.0 (USA);

[0188] The results show:

[0189] Figure 4 a shows that in pancreatic cancer cells with shNFAT1, the expression of NFAT1 gene at the transcriptional level is reduced, and at the same time, the expression level of C-MET gene is also reduced; Figure 4 b shows that after adding NFAT1 inhibitor to pancreatic cancer cells, the expression of NFAT1 gene at the transcriptional level was reduced, and the expression level of C-MET gene was reduced; at the transcriptional level, the NFAT1 knockdown model and the inhibitor model were used to verify that while the expression of NFAT1 gene was reduced, the expression level of C-MET gene would also be reduced.

[0190] 2) After the experiment, the protein concentration was determined by the BCA method. According to the method of determining the protein concentration by the BCA method, the protein concentration was measured using a BCA kit, and then a WB experiment was performed to verify the expression of NFAT1 and C-MET proteins after using the NFAT1 inhibitor at the protein level.

[0191] The results show:

[0192] Figure 4c The results showed that at the protein level, after adding the NFAT1 inhibitor, 10uM of the NFAT1 inhibitor reduced the expression of the NFAT1 protein level, and at the same time, the expression of the C-MET gene also decreased;

[0193] 3) Cell scratch assay

[0194] Take the cells grown to 90%-100% in a 6cm culture dish and evenly draw a well with a sterile 10μL pipette tip. Discard the original RPMI culture medium, wash the excess floating cells at the scratch with PBS, and then add serum-free culture medium. The experimental group added NFAT1 inhibitor according to the pre-calculated drug concentration, and the control group added the same dose of DMSO for culture. Take pictures and collect data at 0h, 16h, 24h, 32h, and 48h.

[0195] The results show:

[0196] Figure 4 d shows that the migration ability of pancreatic cancer cells decreased after the addition of NFAT1 inhibitor, as verified by cell scratch assay.

[0197] 4) Transwell experiment

[0198] The cells in good growth state were digested with 0.25% trypsin, neutralized and diluted with complete RPMI medium, and then resuspended and counted by pipetting. The cells were plated on a sterile 12-well plate, 700 μl of complete RPMI medium was added to each well of the lower chamber, and 4×10 4 cells and 500 μl of culture medium containing 1% serum, and check to confirm that there are no bubbles between the bottom membrane of the upper chamber and the culture medium in the lower chamber. The experimental group added NFAT1 inhibitor according to the pre-calculated drug concentration, and the control group added the same dose of DMSO. After culturing in a 37°C, 5% CO2 incubator for 72 hours, the Transwell chamber was removed, the original culture medium was discarded, and 1xPBS was rinsed twice, and then fixed with 75% ethanol for 20 minutes. After fixation, 500 μl of 0.1% crystal violet was added for 20 minutes, and the upper chamber was wiped dry with a cotton swab after washing with clean water, placed under a 4x microscope, and cell migration images were collected, counted and statistically analyzed.

[0199] The results show:

[0200] Figure 4 e shows that the migration ability of pancreatic cancer cells decreased after adding NFAT1 inhibitors, as verified by transwell invasion chamber experiments; Figure 4 f shows that the migration ability of pancreatic cancer cells overexpressing NFAT1 is improved by transwell invasion chamber experiment. In summary, we conclude that NFAT1 positively regulates C-MET in pancreatic cancer tissues and affects the migration ability of pancreatic cancer cells.

[0201] Example 3: In lung epithelial tissue, NFAT1 positively regulates C-MET, and the addition of NFAT1 inhibitors significantly attenuates the migration of lung epithelial cells

[0202] Specific implementation methods

[0203] 1. BEAS-2B cell culture

[0204] (1) Cell recovery

[0205] Irradiate with ultraviolet light in the clean bench of the cell room for 15 minutes, heat the water bath to 37°C in advance, thaw BEAS cells in the water bath, put the thawed cells into a centrifuge, and centrifuge at 1000 rpm for 5 minutes. After the centrifugation, take out the cryopreservation tube and discard the cryopreservation solution, add 1 ml of DMEM complete culture medium to resuspend the cells, and obtain the resuspended BEAS cells;

[0206] After adding 500ul of DMEM complete culture medium to the T12.5 cell culture flask to moisten the flask, the resuspended BEAS cells were transferred to the above T12.5 culture flask, the flask was shaken to evenly disperse the BEAS cells, and then cultured in a constant temperature incubator at 37°C and 5% CO2.

[0207] (2) Cell passaging

[0208] Observe the cells in the culture flask under a microscope. If the cell density reaches 90% and the cells are in good condition, they can be subcultured. The specific method is:

[0209] Discard the culture medium in the original culture bottle, rinse the cells with 750ul of 1x PBS, and discard the buffer; add 750ul of trypsin to the culture bottle, tighten the bottle cap and tap the bottle for about 1 minute. After the cells are fully digested, add 1000ul of DMEM complete culture medium to the bottle to terminate the digestion and obtain a cell suspension;

[0210] The cell suspension was transferred to a 10 ml centrifuge tube, centrifuged at 1000 rpm for 5 min, the supernatant was discarded, and the cells were resuspended in DMEM complete medium to obtain a cell suspension;

[0211] The cell suspension was transferred to three six-well plates containing DMEM complete culture medium at a volume ratio of 1:3 for subculture, and the conditions were: cultured in a constant temperature incubator at 37° C. and 5% CO 2 .

[0212] The cultured BEAS cells were obtained.

[0213] 2. Establishment of NFAT1 inhibition cell model

[0214] NFAT1 inhibitors were prepared in DMSO, and the stock concentration of the stock solution was 1 mM.

[0215] 1) When the density of the cultured CFPAC-1 pancreatic cancer cells obtained in step 1 reaches about 90%, the cells are passaged twice into a sterile 12-well plate, the cells are evenly dispersed, and cultured in a constant temperature incubator at 37° C. and 5% CO2 for about 24 hours (the cell density reaches about 60% and is evenly distributed);

[0216] 2) Add drugs to the above-mentioned sterile 12-well plate cells, and set up a DMSO control group and NFAT1 inhibitor experimental groups with concentrations of 50nM, 100nM, 500nM, and 1μM, respectively. The specific method is to directly add the original drug diluted to the corresponding concentration to the cultured cells, and culture them in a 37°C, 5% CO2 incubator for 24h.

[0217] The specific groups and treatment methods are as follows:

[0218] DMSO control group: DMSO was added to the cultured cells as a control, and the final concentrations of DMSO were: 50nM, 100nM, 500nM, 1μM; the control groups were: DMSO-50nM group, DMSO-100nM group, DMSO-500nM group, DMSO-1μM group; the control groups were placed in a 37°C, 5% CO2 incubator and cultured for 24h

[0219] 50 nM NFAT1 inhibitor group: Add 50 nM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0220] 100 nM NFAT1 inhibitor group: Add 100 nM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0221] 500 nM NFAT1 inhibitor group: Add 500 nM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0222] 1 μM NFAT1 inhibitor group: Add 1 μM NFAT1 inhibitor to the cultured cells and culture them in a 37°C, 5% CO2 incubator for 24 h;

[0223] Specific as Figure 8 shown.

[0224] The results show:

[0225] Figure 5a The results show that the expression of NFAT1 protein decreased after using NFAT1 inhibitor at the protein level. At the same time, the expression of C-MET protein decreased, and the effective concentration of NFAT1 inhibitor in lung epithelial cells was 100nM; Figure 5 b shows that the migration ability of BEAS cells decreased after adding 100 nM NFAT1 inhibitor, as verified by transwell invasion chamber experiment; Figure 5 c shows that the migration ability of BEAS cells decreased after the addition of NFAT1 inhibitors, as verified by cell scratch assay. In summary, we concluded that in lung epithelial tissue, NFAT1 positively regulates C-MET, and the addition of NFAT1 inhibitors significantly weakened the migration of lung epithelial cells.

[0226] Example 4: In pancreatic cancer tissue, NFAT1 and C-MET are positively regulated, and NFAT1 expression is reduced after knocking down C-MET at the transcriptional level

[0227] Specific implementation methods

[0228] (1) Establishment of pancreatic cancer cell model with C-MET knockdown

[0229] 1) 293T cells (purchased from: Prosai) and ASPC-1 pancreatic cancer cells were laid in advance. When the cell density reached 60-70%, transfection could be started.

[0230] 2) Aspirate and discard the original DMEM basal medium in the 293T cells, replace it with serum-free and anti-antibody-free DMEM basal medium (purchased from Dalian Meilun Company), and use DMEM basal medium to dilute Lipofectamine TM 3000 reagent, let stand at room temperature for 5 min.

[0231] 3) Add lentiviral plasmids (second-generation lentiviral plasmids - pMD2.G, psPAX2) and core plasmids (sh C-MET) at a ratio of pMD2.G:psPAX2:core plasmid = 2:2:1, mix gently, and place at room temperature for 15 minutes. TM 3000 reagents were added to the above mixed plasmids to obtain a mixed solution.

[0232] The mixed solution was dripped into the 293T cell culture medium obtained in step 2), and placed in a 37°C, 5% CO2 incubator for transfection for 6-10 hours, and then serum-free and dual-antibody-free DMEM basal culture medium containing 10% FBS was added, and cultured for 24 hours to obtain a virus suspension;

[0233] Remove the old culture medium in the ASPC-1 pancreatic cancer cells in step 1) and add a small amount of RPMI complete culture medium containing 10% FBS. Use a 1 mL syringe to absorb the virus suspension in the above 293T cells, filter it through a 0.45 μm filter membrane, and then add it to the corresponding ASPC-1 pancreatic cancer cells.

[0234] Then, an appropriate amount of 1 μg / mL polybrene was added to the ASPC-1 pancreatic cancer cell culture medium.

[0235] 4) Then, according to the above method, ASPC-1 pancreatic cancer cells were infected for the second time and the third time at 48 hours and 72 hours after transfection, respectively.

[0236] After three infections, the culture medium of ASPC-1 pancreatic cancer cells was replaced with full RPMI culture medium containing 10% FBS and 1% double antibody (a mixture of 100U / ml penicillin and 100μg / ml streptomycin). When the cells grew well, filtered sterile 1μg / mL puromycin was added to the culture medium and screened for 14 days. During this period, the cell status was carefully observed and the full culture medium containing puromycin was replaced every 2-3 days.

[0237] Finally, a pancreatic cancer cell model with knockdown of C-MET was obtained. After the experiment, the relative expression levels of NFAT1 and C-MET in the ASPC-1 cell model with sh C-MET were detected, and the results were as follows:

[0238] Experimental results:

[0239] After the experiment, total RNA was extracted from cells using 2 -ΔΔCT Methods The relative expression of NFAT1 and C-MET in the ASPC-1 cell model of sh C-MET was analyzed to see if there was differential expression, and the data were presented in a bar graph using prism version 8.0 (USA);

[0240] The results show:

[0241] Fig. 9 The results showed that in ASPC-1 pancreatic cancer cells expressing shC-MET, the expression of C-MET gene was reduced at the transcriptional level. Meanwhile, the expression level of NFAT1 gene was also reduced, indicating that there was a positive feedback regulation between NFAT1 and C-MET.

[0242] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. Use of an NFAT1 inhibitor in the preparation of a drug for treating pancreatic cancer or pulmonary fibrosis with elevated cell migration levels, characterized in that: The drug is used to reduce the expression level of NFAT1 gene in pancreatic cancer and lung epithelium.

2. The use according to claim 1, characterized in that: The medicine contains the above NFAT1 inhibitor and pharmaceutically acceptable excipients.

3. The use according to claim 1 or 2, characterized in that: The inhibitor includes a nucleic acid inhibitor or a protein inhibitor; preferably, the nucleic acid inhibitor includes siRNA, shRNA, ribozyme, antisense oligonucleotide; preferably, the protein inhibitor includes an antibody that neutralizes NFAT1.

4. The use according to claim 1 or 2, characterized in that: The NFAT1 inhibitor includes the interfering RNA sequence and a vector, wherein the vector is a viral vector or a non-viral vector; preferably, the viral vector includes a lentivirus, a pseudovirus, adenovirus, adeno-associated virus, foamy virus, herpes simplex virus, antiretrovirus, and cytomegalovirus vector; the non-viral vector includes an artificially synthesized or natural compound that can form a complex with plasmid DNA or a gene editing fragment and promote intracellular gene transfer; the carrier material is such as lipids, polymers, proteins and polypeptides, and exosomes can be used to carry the interfering RNA sequence or a recombinant gene fragment containing the interfering RNA sequence; the reagent for inhibiting the NFAT1 gene includes shRNA of the NFAT1 gene, siRNA of the NFAT1 gene, a small molecule compound that inhibits the expression of the NFAT1 gene, and a monoclonal antibody to NFAT1; wherein the TT at the 3' end of the sense chain is two pendant bases.

5. A method for screening drugs, characterized in that: The drug is a C-MET inhibitor, and the method comprises: In the test group, the test compound is added to the culture system, and the expression amount and / or activity of NFAT1 in the test group is observed; in the control group, the test compound is not added to the same culture system, and the expression amount and / or activity of NFAT1 in the control group is observed; If the expression level and / or activity of NFAT1 in the test group is lower than that in the control group, it indicates that the test compound is a C-MET inhibitor.

6. The method according to claim 5, characterized in that In the test group, the test compound was co-incubated with CFPAC-1 pancreatic cancer cells, and the expression level and / or activity of NFAT1 was detected.

7. A method for constructing a cell model for screening C-MET inhibitors, characterized in that: The method comprises: in a test group, adding a test compound to a culture system, co-incubating the test compound with CFPAC-1 pancreatic cancer cells, and observing the expression amount and / or activity of NFAT1 in the test group; in a control group, not adding the test compound to the same culture system, and observing the expression amount and / or activity of NFAT1 in the control group; If the expression level and / or activity of NFAT1 in the test group is lower than that in the control group, it indicates that the test compound is a C-MET inhibitor.

8. A method for screening drugs that reduce lung epithelial cell migration, characterized in that: The method comprises: in a test group, adding a test compound to a culture system, and observing the expression amount and / or activity of NFAT1 and / or C-MET in the test group; in a control group, not adding a test compound to the same culture system, and observing the expression amount and / or activity of NFAT1 and / or C-MET in the control group; If the expression level and / or activity of NFAT1 and / or C-MET in the test group is lower than that in the control group, it indicates that the test compound is a drug that weakens the migration of lung epithelial cells, and the drug is used to treat pulmonary fibrosis.

9. A method for constructing a cell model for screening drugs that reduce lung epithelial cell migration, characterized in that: The method comprises: in a test group, adding a test compound to a culture system, co-incubating the test compound and BEAS-2B cells, and observing the expression amount and / or activity of NFAT1 and / or C-MET in the test group; in a control group, not adding a test compound to the same culture system, and observing the expression amount and / or activity of NFAT1 and / or C-MET in the control group; If the expression level and / or activity of NFAT1 and / or C-MET in the test group is lower than that in the control group, it indicates that the test compound is a drug that weakens the migration of lung epithelial cells, and the drug is used to treat pulmonary fibrosis.

10. Use of NFAT1 gene in the preparation of a kit for diagnosing or treating pancreatic cancer with increased cell migration level and pulmonary fibrosis.